research Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents
Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
Search
for
Sort by
Research
30 / 1000+ results 
research Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies
Fulvestrant solution doesn't help hair loss in men and postmenopausal women.
research Incidence of alopecia from endocrine therapies in cancer
Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
research Onychomatricoma with classic features: Case report and review of the literature
Hair loss is a common side effect of hormone treatments for cancer.
research An estrogen receptor pathwayregulates thetelogen-anagen hair follicle transition andinfluences epidermal cell proliferation (epidermis/estrogen/keratinocyte/differentiation/mesenchymal
The estrogen receptor pathway controls hair growth cycles and affects skin cell growth.
research Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion
Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
research Hormone Blocking Anticancer Drugs
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
research NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
The document discusses the submission of a New Drug Application (NDA) to the U.S. FDA for vepdegestrant (ARV-471), a PROTAC protein degrader targeting the estrogen receptor, by Arvinas and Pfizer. This submission is based on positive results from the Phase 3 VERITAC-2 trial and marks a significant milestone as vepdegestrant is anticipated to be the first FDA-approved PROTAC degrader. PROTACs, a novel class of molecules, selectively degrade disease-causing proteins and offer advantages over traditional small molecule inhibitors, such as mitigating off-target effects and overcoming drug resistance. Despite concerns about their large molecular weight and drug-like properties, recent clinical results have been promising. The success of PROTACs has inspired the development of other chimeric molecules for therapeutic applications.
research Formestane Preferred as Second-Line Therapy in Advanced Breast Cancer
Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.
research 105 Spironolactone May be a Cause of Hormonally Associated Vestibulodynia and Female Genital Arousal Disorder
Spironolactone may cause sexual pain and arousal issues in women, which can improve after stopping the drug and using hormone cream.
research Deslorelin for the treatment of hair cycle arrest in intact male dogs
Deslorelin may help intact male dogs regrow hair from alopecia X, with a 75% success rate and no side effects.
research Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique
Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.
research Insulin resistance and hair disorders, idiopathic hirsutism, and androgenic alopecia
There is no significant link between insulin resistance and certain hair disorders like idiopathic hirsutism and androgenic alopecia.
research Minimal systemic exposure of a new topical triazole antifungal, efinaconazole 10% solution, in patients with severe onychomycosis following 28-day treatment
Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.
research Finasteride/spironolactone
research Progestogens with Antiandrogenic Properties
research Finasteride/flibanserin
research Spironolactone May be a Cause of Hormonally Associated Vestibulodynia and Female Sexual Arousal Disorder
Spironolactone might cause painful intercourse and decreased sexual arousal in women.
research FASCE, benefit of spironolactone for treating acne of adult female: study protocol for a randomized double-blind trial
Spironolactone may be a better acne treatment for adult women than antibiotics.
research Anticancer drugs in surface waters
Anticancer drugs are increasingly found in surface waters, and their long-term environmental effects are not well understood, requiring better testing methods.
research Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men
Use minoxidil for hair loss; finasteride and dutasteride for men, dutasteride for women.
research Androgenetic Alopecia: An Evidence-Based Treatment Update
Effective treatments for male pattern baldness include oral finasteride and topical minoxidil, while topical minoxidil is best for female pattern baldness.
research Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version
Use minoxidil for hair loss treatment; assess results after 6 months.
research Predicting therapeutic drugs for hepatocellular carcinoma based on tissue-specific pathways
Securinine and ajmaline may effectively treat liver cancer, with securinine being less toxic to normal cells.
research Revising the role of the androgen receptor in breast cancer
The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.
research Effect of estrogens on skin aging and the potential role of selective estrogen receptor modulators
Estrogens and SERMs can help with skin aging, but their safety and effectiveness need more research.
research Hair disorders in patients with cancer
Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.
research Alopecia With Endocrine Therapies in Patients With Cancer
Endocrine therapies for cancer significantly increase the risk of hair loss.
research Sulfatase inhibitors: a patent review
The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.
research Hair: What is New in Diagnosis and Management?
Female pattern hair loss diagnosed by scalp appearance, treated with combined therapies and targeted approaches.